Trevi Therapeutics Stock Investor Sentiment

TRVI Stock  USD 2.88  0.04  1.37%   
Under 67% of Trevi Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Trevi Therapeutics stock suggests that many investors are alarmed at this time. Trevi Therapeutics' investing sentiment shows overall attitude of investors towards Trevi Therapeutics.
  

Trevi Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Trevi Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a year ago at www.macroaxis.com         
Acquisition by Vanlent Anne of 30000 shares of Trevi Therapeutics subject to Rule 16b-3
Macroaxis News
over a year ago at news.google.com         
Trevi Therapeutics Files for 150 Million Mixed Shelf Offering to ... - Best Stocks
Google News at Macroaxis
over a year ago at www.macroaxis.com         
Exercise or conversion by Simon Farrell of 6250 shares of Trevi Therapeutics subject to Rule 16b-3
Macroaxis News
over a year ago at news.google.com         
Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer - ...
Google News at Macroaxis
over a year ago at finance.yahoo.com         
Trevi Therapeutics, Inc.s top owners are private equity firms with 35 percent stake, while 32 percen...
Yahoo News
over a year ago at hawaiinewsnow.com         
Trevi Therapeutics to Participate in Upcoming June Conferences
news
over a year ago at investing.com         
Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial
Investing News at Macroaxis
over a year ago at insidermonkey.com         
Trevi Therapeutics, Inc. Q1 2023 Earnings Call Transcript
insidermonkey News
over a year ago at finance.yahoo.com         
Trevi Therapeutics, Inc. Q1 2023 Earnings Call Transcript
Yahoo News
over a year ago at investing.com         
Trevi Therapeutics earnings beat by 0.01, revenue was in line with estimates
Investing News at Macroaxis
over a year ago at finance.yahoo.com         
Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update
Yahoo News
over a year ago at finance.yahoo.com         
Is a Surprise Coming for Trevi Therapeutics This Earnings Season?
Yahoo News
over a year ago at zacks.com         
Is a Surprise Coming for Trevi Therapeutics This Earnings Season?
zacks News
over a year ago at hawaiinewsnow.com         
Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023
news
over a year ago at hawaiinewsnow.com         
Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 202...
news
Far too much social signal, news, headlines, and media speculation about Trevi Therapeutics that are available to investors today. That information is available publicly through Trevi media outlets and privately through word of mouth or via Trevi internal channels. However, regardless of the origin, that massive amount of Trevi data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Trevi Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Trevi Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Trevi Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Trevi Therapeutics alpha.

Trevi Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 3863 shares by Jennifer Good of Trevi Therapeutics at 1.43 subject to Rule 16b-3
09/03/2024
2
Disposition of 4219 shares by Jennifer Good of Trevi Therapeutics at 1.43 subject to Rule 16b-3
09/06/2024
3
Disposition of 1840 shares by Jennifer Good of Trevi Therapeutics at 1.43 subject to Rule 16b-3
09/09/2024
4
Trevi Therapeutics, Inc. Given Average Rating of Buy by Analysts - MarketBeat
09/24/2024
5
Acquisition by James Cassella of 400000 shares of Trevi Therapeutics at 3.34 subject to Rule 16b-3
09/30/2024
6
Trevi Therapeutics Provides Update on Haduvios Clinical Development Program
10/03/2024
7
Trevi Therapeutics Inc Q2 2024 Earnings Call Highlights Navigating Financial Challenges ...
10/09/2024
8
Trevi Therapeutics Given Buy Rating at HC Wainwright
10/22/2024
9
Trevi Therapeutics EPS of -0.13 misses by 0.02
11/06/2024
10
Trevi Therapeutics Inc Q3 2024 Earnings Call Highlights Navigating Increased Losses and ...
11/07/2024
11
Trevi Therapeutics, Inc. Receives 7.43 Average PT from Brokerages - MarketBeat
11/13/2024
12
Landscape Capital Management L.L.C. Sells 180,717 Shares of Trevi Therapeutics, Inc.
11/22/2024

Complementary Tools for Trevi Stock analysis

When running Trevi Therapeutics' price analysis, check to measure Trevi Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trevi Therapeutics is operating at the current time. Most of Trevi Therapeutics' value examination focuses on studying past and present price action to predict the probability of Trevi Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trevi Therapeutics' price. Additionally, you may evaluate how the addition of Trevi Therapeutics to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Fundamental Analysis
View fundamental data based on most recent published financial statements
Money Managers
Screen money managers from public funds and ETFs managed around the world
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk